Literature DB >> 1251756

Determination of monoamine and monoamine metabolites in the human brain: post mortem studies in a group of suicides and in a control group.

J Beskow, C G Gottfries, B E Roos, B Winblad.   

Abstract

Different nuclei and regions of the brain from patients who had committed suicide and from controls were analysed for their content of monoamine and monoamine metabolites. There was a post mortem breakdown of 5-hydroxyindoleacetic acid (5-HIAA) which could be correlated to the time elapsed between the occurrence of death and autopsy. Homovanillic acid (HVA) and the monoamines did not decrease post mortem during the time observed (6-148 hours). There was no significant correlation between age and chemical variables in this investigation. There were no significant group differences between suicides and controls concerning dopamine, noradrenaline, 5-hydroxytryptamine, and HVA, 5-HIAA levels were significantly lower in the suicide group in six out of eight parts of the brain investigated. It was, however, also demonstrated that there was a longer time elapse between the occurrence of death and autopsy in the suicide group. The suicides came on average 48 hours later to autopsy than the controls. As there was a post mortem decrease of 5-HIAA, this time variable had to be kept constant when group differences were analysed. When the influence of this time variable was eliminated there were no longer any differences between suicides and controls. According to this investigation, there seem to be no differences in levels of monoamines and their metabolites between suicides and controls.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1251756     DOI: 10.1111/j.1600-0447.1976.tb00054.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  19 in total

1.  Brain 5-HT1 binding sites in depressed suicides.

Authors:  S C Cheetham; M R Crompton; C L Katona; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex.

Authors:  M D Galva; G P Bondiolotti; M Olasmaa; G B Picotti
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  Brain beta-adrenoceptor binding sites in depressed suicide victims: effects of antidepressant treatment.

Authors:  F De Paermentier; S C Cheetham; M R Crompton; C L Katona; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 4.  Stress, genes and the biology of suicidal behavior.

Authors:  Dianne Currier; J John Mann
Journal:  Psychiatr Clin North Am       Date:  2008-06

5.  Brain 5-hydroxytryptamine uptake sites labeled with [3H]paroxetine in antidepressant drug-treated depressed suicide victims and controls.

Authors:  K M Lawrence; F De Paermentier; S Lowther; M R Crompton; C L Katona; R W Horton
Journal:  J Psychiatry Neurosci       Date:  1997-05       Impact factor: 6.186

6.  Lower 3H-paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high affinity, non-transporter sites.

Authors:  J J Mann; R A Henteleff; T F Lagattuta; J A Perper; S Li; V Arango
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

7.  N-3 (omega-3) Fatty acids in postpartum depression: implications for prevention and treatment.

Authors:  Beth Levant
Journal:  Depress Res Treat       Date:  2010-10-27

Review 8.  Dopamine and depression.

Authors:  A S Brown; S Gershon
Journal:  J Neural Transm Gen Sect       Date:  1993

9.  Brain gamma-aminobutyrate transaminase and monoamine oxidase activities in suicide victims.

Authors:  F Sherif; J Marcusson; L Oreland
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

10.  Regional studies of serotonin and dopamine metabolism and quantification of serotonin uptake sites in human cerebral cortex.

Authors:  B Parsons; A Roxas; Y Y Huang; A Dwork; M Stanley
Journal:  J Neural Transm Gen Sect       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.